RESULTS: Subjects were with the following mean values: mean duration of diseases 18.3±6.74 years, Total IgE serum levels: 414.5±161.1 U/mL; FEV1/FVC: 53.1±6.98 %; FEV1 47.5±6.95 %. The exacerbation rate reduced significantly from 19.66±8.57/y (mean ± SD) to 3±3.09, and the hospitalization rate reduced from 1.16±0.98/y to 0.16±0.4 at 12 months (p=0.002 and p=0.034,respectively). After omalizumab treatment was initiated, the patients' mean oral corticosteroid dosage significantly decreased (p=0.001). In two patients, steroid treatment was stopped. We did not observe significant change in FEV1 values at 4 months, however, it improves significantly following 12 months (p<0.05). Four of the patients (66.7%) responded perfectly, and two (33.3%) partially responded to treatment.